Chlorion Pharma Inc.

Chlorion Pharma Inc. is a pharmaceutical company specializing in innovative treatments and therapies to improve patient outcomes. The company focuses on developing essential healthcare solutions in the biopharmaceutical sector. Chlorion Pharma Inc.

operates in the biopharmaceutical sector, focusing on developing and delivering innovative healthcare solutions. Founded in 2004 in Laval, Canada, the company has undergone a business transformation and pivoted towards specialized pharmaceuticals. As of November 2011, the company has ceased operations. Chlorion Pharma Inc.

has completed a total of 3 deals, with the most recent deal occurring on November 28, 2011. The last funding round was Venture Debt, securing USD 4. 00 mn from investors AgeChem and CTI Life Sciences, contributing to a total of USD 6. 00 mn raised.

Chlorion. com specializes in offering premium domain names, with a core focus on the facilitation of domain registration and ownership transfer. The company's services are designed to streamline the process of acquiring desirable web addresses for various businesses and individual users, enhancing their online presence. The key features include seamless domain transfer processes, flexible payment plans, and a customer-centric approach to domain acquisition.

Chlorion. com caters to a diverse clientele, including entrepreneurs, small businesses, and established corporations seeking to secure unique digital identifiers. The company's offerings are available in global markets, providing access to customers in North America, Europe, and Asia, among others. ChlorIon.

com generates revenue primarily through the sale of domain names, with structured transactions that include both direct purchases and flexible payment plans. Customers can choose to acquire domains through a one-time payment or opt for a monthly installment plan, enabling them to manage cash flow more effectively. The company’s flagship products include premium domain names priced at USD 795, with additional options for monthly payments set at USD 66. 25 over a 12-month period.

This structured pricing model attracts a wide range of clients from different sectors, facilitating both B2B and direct-to-consumer transactions. The revenue is driven by the growing demand for digital assets as businesses seek to establish their online identities. In November 2011, Chlorion Pharma Inc. went out of business; therefore, there are no upcoming products, new market expansions, or utilization of recent funding to outline as part of its future growth plans.